The president of the Pharmaceutical Industries Association (ADIFAN), José Silva, explained that Peruvian laboratories are at disadvantage compared to foreign manufacturers who are favored by tariff exemptions.

Due to this situation, Peruvian laboratories manufacture less quantity of medicines, causing up to 70% of medicines in Perú to be imported and only the remaining 30% to be national production.

In this regard, the National Institute of Research and Statistics (INEI) has established that the production of the national pharmaceutical industry has been declining from 2013 until 2017 when it grew by 10%.

The president of ADIFAN said that Perú imports medicines for an amount of USD 1.3 billion and only exports USD 69 million.

Source: Gestión

The Peruvian government published the regulation of the Emergency Decree No. 007-2019 that guarantees access to generic drugs, biological products, and medical devices as an essential part of the right to health.

• Aminotriptiline

• Amlodipine

• Amoxicillin

• Amoxicillin/clavulanate

• Atorvastatin

• Azithromycin

• Beclometasone

• Captopril

• Carbamazepine

• Cefalexin

• Clindamycin

• Clonazepam

• Clorphenamin

• Clotrimazole

• Enalapril

• Phenytoin

• Fluconazole

• Fluoxetine

• Glibenclamide

• Ibuprophen

• Loratadine

• Losartan

• Metformin

• Naproxen

• Omeprazole

• Acetaminophen

• Prednisone

Learn more about the Peruvian pharmaceutical market at 997556699 or by mail info@pharmaconsulting.pe